A Phase 1 interventional study of LY3074828 and LY3074828 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected.
Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 12 weeks, not including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Healthy participants.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-milligram/milliliter \[mg/mL\]) administered subcutaneously (SC) via an auto-injector (AI) in arm.
Biological: LY3074828 · Device: Auto-injector (AI)
Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in thigh.
Biological: LY3074828 · Device: Auto-injector (AI)
Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in abdomen.
Biological: LY3074828 · Device: Auto-injector (AI)
Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm. The second injection was administered 20 (±2) minutes after the first injection.
Drug: LY3074828 · Device: Prefilled syringe (PFS)
Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in thigh. The second injection was administered 20 (±2) minutes after the first injection.
Drug: LY3074828 · Device: Prefilled syringe (PFS)
Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in abdomen. The second injection was administered 20 (±2) minutes after the first injection.
Drug: LY3074828 · Device: Prefilled syringe (PFS)
Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device
Pharmacokinetics: Cmax of LY3074828
Time frame: Day 1: 0, 2, 6 hours (hr), Day 2: 24 hr, Day 4, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Post dose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828 by Device
Pharmacokinetics: Area Under the Concentration versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828
Time frame: Day 1: 0, 2, 6 hours (hr), Day 2: 24 hr, Day 4, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Post dose
Visual Analogue Scale (VAS) Pain Assessment by Device
The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.
Time frame: Day 1: 1, 5 (±1.5) and 15 (±2) minutes
Visual Analogue Scale (VAS) Pain Assessment by Device and Injection Site Location
The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.
Time frame: Day 1: 1, 5 (±1.5) and 15 (±2) minutes
| Milestone | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 |
|---|---|---|---|---|---|---|
| Started | 11 | 11 | 11 | 11 | 11 | 11 |
| Received at least one dose of drug | 11 | 11 | 11 | 11 | 11 | 11 |
| Completed | 11 | 11 | 11 | 11 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Pharmacokinetics: Cmax of LY3074828
| micrograms per milliliter (μg/mL) | 250 mg LY3074828 AI | 250 mg LY3074828 PFS |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device | 22.2 ± 40 | 18.7 ± 34 |
Pharmacokinetics: Area Under the Concentration versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828
| microgram*day per millileter (μg*day/mL) | 250 mg LY3074828 AI | 250 mg LY3074828 PFS |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828 by Device | 357 ± 38 | 340 ± 38 |
The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.
| millimeter | 250 mg LY3074828 AI First Injection | 250 mg LY3074828 PFS First Injection | 250 mg LY3074828 PFS Second Injection |
|---|---|---|---|
| 1 min | 25.2 ± 20.0 | 22.6 ± 18.3 | 18.3 ± 15.1 |
| 5 min (±1.5) | 12.0 ± 15.8 | 6.1 ± 7.0 | 6.0 ± 6.7 |
| 15 min (±2) | 1.9 ± 3.1 | 2.4 ± 2.8 | 2.2 ± 4.3 |
The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.
| millimeter | 250 mg LY3074828 AI First Injection | 250 mg LY3074828 PFS First Injection | 250 mg LY3074828 PFS Second Injection |
|---|---|---|---|
| Arm: 1 min | 25.9 ± 17.2 | 19.0 ± 12.0 | 15.6 ± 12.3 |
| Arm: 5 min (±1.5) | 5.6 ± 5.4 | 4.5 ± 5.5 | 5.0 ± 6.0 |
| Arm: 15 min (±2) | 2.6 ± 4.8 | 1.8 ± 2.4 | 2.0 ± 2.9 |
| Thigh: 1 min | 26.8 ± 15.5 | 19.6 ± 20.9 | 20.5 ± 19.6 |
| Thigh: 5 min (±1.5) | 13.1 ± 12.3 | 6.2 ± 6.6 | 7.9 ± 7.8 |
| Thigh:15 min (±2) | 0.9 ± 1.3 | 3.0 ± 3.6 | 3.5 ± 6.7 |
| Abdomen: 1 min | 22.9 ± 27.2 | 29.2 ± 20.6 | 18.7 ± 13.4 |
| Abdomen: 5 min (±1.5) | 17.4 ± 23.3 | 7.5 ± 8.8 | 5.0 ± 6.4 |
| Abdomen: 15 min (±2) | 2.2 ± 2.1 | 2.4 ± 2.4 | 1.2 ± 1.9 |
Collected over Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test 1: 250 mg LY3074828 | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Test 2: 250 mg LY3074828 | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| Test 3: 250 mg LY3074828 | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Reference 1: 250 mg LY3074828 | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Reference 2: 250 mg LY3074828 | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| Reference 3: 250 mg LY3074828 | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Event | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 |
|---|---|---|---|---|---|---|
| TachycardiaCardiac disorders | 0/11 | 0/11 | 0/11 | 0/11 | 1/11 | 0/11 |
| Refraction disorderEye disorders | 0/11 | 0/11 | 1/11 | 0/11 | 0/11 | 0/11 |
| NauseaGastrointestinal disorders | 0/11 | 0/11 | 0/11 | 0/11 | 1/11 | 0/11 |
| Influenza like illnessGeneral disorders | 1/11 | 1/11 | 0/11 | 1/11 | 0/11 | 0/11 |
| Injection site bruisingGeneral disorders | 0/11 | 1/11 | 1/11 | 1/11 | 0/11 | 1/11 |
| NasopharyngitisInfections and infestations | 0/11 | 0/11 | 0/11 | 0/11 | 1/11 | 0/11 |
| ContusionInjury, poisoning and procedural complications | 0/11 | 1/11 | 0/11 | 0/11 | 0/11 | 0/11 |
| Corneal abrasionInjury, poisoning and procedural complications | 0/11 | 0/11 | 0/11 | 0/11 | 0/11 | 1/11 |
| LacerationInjury, poisoning and procedural complications | 1/11 | 0/11 | 0/11 | 0/11 | 0/11 | 0/11 |
| Limb injuryInjury, poisoning and procedural complications | 0/11 | 0/11 | 0/11 | 0/11 | 1/11 | 0/11 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 44.6 ± 14.3 | 39.9 ± 13.7 | 45.4 ± 9.4 | 44.1 ± 14.7 | 42.8 ± 12.3 | 45.0 ± 12.9 | 43.6 ± 12.6 |
| Sex: Female, Male(Participants) | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 6 | 6 | 6 | 7 | 7 | 39 |
| Male | 4 | 5 | 5 | 5 | 4 | 4 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 5 | 4 | 4 | 7 | 28 |
| Not Hispanic or Latino | 7 | 7 | 6 | 7 | 7 | 4 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 4 | 1 | 4 | 0 | 14 |
| White | 8 | 6 | 6 | 10 | 7 | 11 | 48 |
| More than one race | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Test 1: 250 mg LY3074828 | Test 2: 250 mg LY3074828 | Test 3: 250 mg LY3074828 | Reference 1: 250 mg LY3074828 | Reference 2: 250 mg LY3074828 | Reference 3: 250 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|
| United States | 11 | 11 | 11 | 11 | 11 | 11 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Jan 2019, 4 months.
Results were first posted in Jan 2024, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab